CELL SEARCH SYSTEM -CELL BANK- (RIKEN BRC) [RCB1678 : JHOS-4]

21426 Machino H, Dozen A, Konaka M, Komatsu M, Nakamura K, Ikawa N, Shozu K, Asada K, Kaneko S, Yoshida H, Kato T, Nakayama K, Saloura V, Kyo S, Hamamoto R. Integrative analysis reveals early epigenetic alterations in high-grade serous ovarian carcinomas. Exp Mol Med 2023 PubMed ID: 37779141 DOI: 10.1038/s12276-023-01090-1

21483 Tsuchimochi S, Wada-Hiraike O, Urano Y, Kukita A, Yamaguchi K, Honjo H, Taguchi A, Tanikawa M, Sone K, Mori-Uchino M, Tsuruga T, Oda K, Osuga Y. Characterization of a fluorescence imaging probe that exploits metabolic dependency of ovarian clear cell carcinoma. Sci Rep 2023 13(1):20292 PubMed ID: 37985723 DOI: 10.1038/s41598-023-47637-0

20521 Machino H, Kaneko S, Komatsu M, Ikawa N, Asada K, Nakato R, Shozu K, Dozen A, Sone K, Yoshida H, Kato T, Oda K, Osuga Y, Fujii T, von Keudell G, Saloura V, Hamamoto R. The metabolic stress-activated checkpoint LKB1-MARK3 axis acts as a tumor suppressor in high-grade serous ovarian carcinoma. Commun Biol 2022 5(1):39 PubMed ID: 35017636 DOI: 10.1038/s42003-021-02992-4

20800 Fu L, Zhang D, Yi N, Cao Y, Wei Y, Wang W, Li L. Circular RNA circPBX3 promotes cisplatin resistance of ovarian cancer cells via interacting with IGF2BP2 to stabilize ATP7A mRNA expression. Hum Cell 2022 PubMed ID: 35907138 DOI: 10.1007/s13577-022-00748-8

20428 Yang X, Wu G, Yang F, He L, Xie X, Li L, Yang L, Ma Y, Zhang Q, Chen J, Zou S, Han Q, Wang Y, Liu S, Li J, Han B, Liu K. Elevated LINC00909 Promotes Tumor Progression of Ovarian Cancer via Regulating the miR-23b-3p/MRC2 Axis. Oxid Med Cell Longev 2021 2021:5574130 PubMed ID: 34336102 DOI: 10.1155/2021/5574130

13387 Wada M, Kukita A, Sone K, Hamamoto R, Kaneko S, Komatsu M, Takahashi Y, Inoue F, Kojima M, Honjoh H, Taguchi A, Kashiyama T, Miyamoto Y, Tanikawa M, Tsuruga T, Mori-Uchino M, Wada-Hiraike O, Osuga Y, Fujii T. Epigenetic Modifier SETD8 as a Therapeutic Target for High-Grade Serous Ovarian Cancer. Biomolecules 2020 PubMed ID: 33339442 DOI: 10.3390/biom10121686

13700 Kudo K, Nomura M, Sakamoto Y, Ito S, Morita M, Kawai M, Yamashita Y, Ito K, Yamada H, Shima H, Yaegashi N, Tanuma N. Divergent metabolic responses dictate vulnerability to NAMPT inhibition in ovarian cancer FEBS Lett 2020 594(9):1379-1388 PubMed ID: 31950503 DOI: 10.1002/1873-3468.13736

11501 Kukita A, Sone K, Oda K, Hamamoto R, Kaneko S, Komatsu M, Wada M, Honjoh H, Kawata Y, Kojima M, Oki S, Sato M, Asada K, Taguchi A, Miyasaka A, Tanikawa M, Nagasaka K, Matsumoto Y, Wada-Hiraike O, Osuga Y, Fujii T. Histone methyltransferase SMYD2 selective inhibitor LLY-507 in combination with poly ADP ribose polymerase inhibitor has therapeutic potential against high-grade serous ovarian carcinomas. Biochem. Biophys. Res. Commun. 2019 PubMed ID: 30955858 DOI: 10.1016/j.bbrc.2019.03.155

11511 Behan FM, Iorio F, Picco G, Gonçalves E, Beaver CM, Migliardi G, Santos R, Rao Y, Sassi F, Pinnelli M, Ansari R, Harper S, Jackson DA, McRae R, Pooley R, Wilkinson P, van der Meer D, Dow D, Buser-Doepner C, Bertotti A, Trusolino L, Stronach EA, Saez-Rodriguez J, Yusa K, Garnett MJ. Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens. Nature 2019 PubMed ID: 30971826 DOI: 10.1038/s41586-019-1103-9

18200 Hiramatsu K, Serada S, Enomoto T, Takahashi Y, Nakagawa S, Nojima S, Morimoto A, Matsuzaki S, Yokoyama T, Takahashi T, Fujimoto M, Takemori H, Ueda Y, Yoshino K, Morii E, Kimura T, Naka T. LSR Antibody Therapy Inhibits Ovarian Epithelial Tumor Growth by Inhibiting Lipid Uptake Cancer Res 2018 78(2):516-527 PubMed ID: 29187404 DOI: 10.1158/0008-5472.CAN-17-0910

9659 Elayne Chan-Penebre, Kelli Armstrong, Allison Drew, Alexandra R Grassian, Igor Feldman, Sarah K Knutson, Kristy Kuplast-Barr, Maria Roche, John Campbell, Peter Ho, Robert A Copeland, Richard Chesworth, Jesse J Smith, Heike Keilhack, Scott A Ribich Selective Killing of SMARCA2- And SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: In Vitro and In Vivo Preclinical Models Mol Cancer Ther 2017 16(5):850-860 PubMed ID: 28292935 DOI: 10.1158/1535-7163.MCT-16-0678

9658 Tomoko Kashiyama, Katsutoshi Oda, Yuji Ikeda, Yoshinobu Shiose, Yasuhide Hirota, Kanako Inaba, Chinami Makii, Reiko Kurikawa, Aki Miyasaka, Takahiro Koso, Tomohiko Fukuda, Michihiro Tanikawa, Keiko Shoji, Kenbun Sone, Takahide Arimoto, Osamu Wada-Hiraike, Kei Kawana, Shunsuke Nakagawa, Koichi Matsuda, Frank McCormick, Hiroyuki Aburatani, Tetsu Yano, Yutaka Osuga, Tomoyuki Fujii Antitumor Activity and Induction of TP53-dependent Apoptosis Toward Ovarian Clear Cell Adenocarcinoma by the Dual PI3K/mTOR Inhibitor DS-7423 PLoS One 2014 9(2):e87220 PubMed ID: 24504419 DOI: 10.1371/journal.pone.0087220

9669 Ikue Nakayama, Masahiko Shibazaki, Akiko Yashima-Abo, Fumiharu Miura, Toru Sugiyama, Tomoyuki Masuda, Chihaya Maesawa Loss of HOXD10 Expression Induced by Upregulation of miR-10b Accelerates the Migration and Invasion Activities of Ovarian Cancer Cells Int J Oncol 2013 43(1):63-71 PubMed ID: 23670532 DOI: 10.3892/ijo.2013.1935

15560 Suzuki F, Akahira J, Miura I, Suzuki T, Ito K, Hayashi S, Sasano H, Yaegashi N. Loss of estrogen receptor beta isoform expression and its correlation with aberrant DNA methylation of the 5'-untranslated region in human epithelial ovarian carcinoma. Cancer Sci 2008 99:2365-72 PubMed ID: 19032364 DOI: 10.1111/j.1349-7006.2008.00988.x